Shanghai Medicilon Inc.

  On March 22, the 2024 Shanghai Industrial Technology Innovation Conference was held with the theme of "Building the Main Engine of Innovation and Seizing New Opportunities in the Future".  At this conference, Medicilon won the "2024 Shanghai Hard Core Technology Enterprises TOP100 List" with its hard-core technology and innovative technology service platform in the preclinical field of biopharmaceutical. As a one-stop biopharmaceutical preclinical R&D service platform, Medicilon has always been committed to exploring hard-core technologies in the biopharmaceutical preclinical field.  After 20 years of development, Medicilon now has 84,000 square meters of R&D laboratories and a high-quality R&D team.  Through continuous technological innovation and R&D investment, we have conquered the core R&D technologies of new molecular types of drugs such as antibodies, peptides,  ADCs ,  PROTACs ,  mRNA vaccines , small nucleic acid drugs, c...